HT0203
Specimen Requirement |
10 unstained sections of tumour and a corresponding H&E-stained histological section, OR 1 paraffin block of tumour |
Orderable as Urgent? | No |
Turn Around Time |
5 working days
|
Testing Laboratory Location | KKH |
Laboratory | Molecular Pathology |
Contact Number | 6394 1402 |
Day and Time Performed |
Mon – Fri: 0800 hrs – 1700 hrs
|
Orderable on CPOE? | No |
Downtime Form | |
Additional Information |
Background Adult-type granulosa cell tumours of the ovary (aGCTs) are rare tumours that represent 2–5% of ovarian malignancies. The prognosis of this tumour is favourable, and it is characterized by slow progression. 10–30% of these tumours recur after 4–7 years of the primary surgery and the 5-year survival rate from the first recurrence is 55%, for the incompletely resected patients. Heterozygous point mutation of c.402C>G in the FOXL2 gene can be found in 97% of cases of aGCT. Purpose of test The test identifies the specific FOXL2 point mutation c.402C>G p.Cys134Trp (p.C134W) by Sanger sequencing. Expected test result FOXL2 c.402C>G mutation detected/not detected. Caveats DNA integrity and concentration must meet assay requirements. Low tumour content (<50%) may result in a false negative result. Proficiency testing Alternative performance assessment programme. References 1.Schrader
KA et al The specificity of the FOXL2 c.402C>G somatic mutation: a survey of
solid tumors PLoS One.
2009 Nov 24;4(11):e7988 2.Kommoss S et
al FOXL2 molecular testing in ovarian neoplasms: diagnostic approach and
procedural guidelines. Mod Pathol. 2013
Jun;26(6):860-7 3.Shah SP et al Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med. 2009 Jun 25;360(26):2719-29 |
Change History Notes
18 Jun 2025 04:02 PM
Update downtime form
12 Apr 2024 04:00 PM
Update of specimen requirement, test name, additional information and editorial edit
06 Oct 2022 12:00 AM
Updates Test Name, Test Code.
Last Updated - 27 Jun 2025
Stay Healthy With
© 2025 SingHealth Group. All Rights Reserved.